<DOC>
	<DOCNO>NCT01907880</DOCNO>
	<brief_summary>Metastatic breast cancer patient bone involvement high-risk subsequent skeletal related event ( SRE ) , define radiotherapy surgery bone , pathological fracture , spinal cord compression , hypercalcemia ( reflect : elevate sCTX bone pain prior SRE despite receive standard bisphosphonate therapy ) experience decrease surrogate marker , sCTX , week 12 switch zoledronic acid compare patient continue intravenous pamidronate ( i.e . current standard care ) . The investigator propose drop sCTX correlate improve pain , quality life reduce incidence SREs .</brief_summary>
	<brief_title>The ODYSSEY TRIAL Phase IV Trial Evaluating Palliative Benefit Pamidronate Zoledronic Acid Breast Cancer</brief_title>
	<detailed_description>This study prospective , randomize , double-blind , placebo control , Phase IV study pamidronate vs. zoledronic acid woman breast cancer bone metastasis . Patients high-risk subsequent SREs screen entry study . High-risk define fulfil one follow criterion : elevate sCTX ( &gt; 400ng/L ) and/or bone pain and/or prior SRE and/or progression bone disease ( image ) despite least 3 month pamidronate therapy . Patients meet eligibility criterion , randomize receive 3 cycle intravenous zoledronic acid ( 4mg intravenously 15 minute ) continue standard dose pamidronate . Both treatment give 4 week interval . Patients stratify accord whether SRE prior study entry , progressive bone disease bone pain . In order study double-blind , patient receive two infusion simultaneously , study visit , one active drug another placebo . After complete 3 cycle study treatment , patient resume monthly intravenous pamidronate infusion per current standard care .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Metastatic breast cancer bone radiologically confirm bone metastasis 2 . Highrisk subsequent SRE reflect either : elevate serum CTX ( &gt; 400ng/L ) and/or bone pain ( use BPI ) and/or prior SRE bisphosphonate therapy and/or progressive bone metastasis ( image ) 3 . On pamidronate therapy least 3 month 4 . ECOG ≤ 2 life expectancy &gt; 3 month 5 . Serum creatinine ≤ 2.0 × ULN ( zoledronic acid pamidronate renal dose per institution standard ) 6 . No change systemic treatment 4 week prior study entry anticipate change 4 week enter study . Markers bone formation affect change systemic therapy 7 . Ability take calcium Vitamin D per Health Canada recommend daily dos duration study 8 . Ability provide inform consent complete study evaluation . 1 . Patients acute symptomatic pathological fracture acute spinal cord compression time appropriate management ( surgery and/or radiotherapy ) complete 2 . Acute hypercalcemia ( &gt; 3.5 mmol/L ) 3 . Hypersensitivity bisphosphonate 4 . Patients rapidly progressive nonbone metastasis delay change systemic anticancer treatment 1 month biochemical marker evaluation period could detrimental impact patient outcome . 5 . Renal dysfunction ( ≥ 2x creatinine upper limit normal ) 6 . Pregnancy lactation 7 . Patients dental abscess patient potentially require tooth extraction study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>breast</keyword>
	<keyword>bone</keyword>
	<keyword>pain</keyword>
</DOC>